StimCell Enegetics

StimCell Enegetics Current Liabilities

The Current Liabilities of StimCell Enegetics (STME) as of Oct 21, 2026 is 356,302.00 USD. In the previous year, Current Liabilities was 835,070.00 USD — a change of -57.33% (lower).

Current Liabilities

356,302.00USD

YoY

-57.33%

Last updated:

Current Liabilities of StimCell Enegetics is 2026 356,302.00 USD. Current Liabilities of StimCell Enegetics was 2025 835,070.00 USD. It decreases by -57.33% lower compared to the previous year.

The StimCell Enegetics Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2019
1.68 M USD
Jan 1, 2020
1.71 M USD
Jan 1, 2021
1.66 M USD
Jan 1, 2022
471,339.00 USD
Jan 1, 2023
2.53 M USD
Jan 1, 2024
900,676.00 USD
Jan 1, 2025
835,070.00 USD
Jan 1, 2026
356,302.00 USD
The StimCell Enegetics Current Liabilities history
YEARCurrent LiabilitiesYoY
356,302.00USD-57.33%
835,070.00USD-7.28%
900,676.00USD-64.33%
2.53 MUSD+435.78%
471,339.00USD-71.67%
1.66 MUSD-2.95%
1.71 MUSD+1.97%
1.68 MUSD+54.54%
1.09 MUSD-27.11%
1.49 MUSD-10.56%
1.67 MUSD+119.25%
760,930.00USD+3,423.48%
21,596.00USD+68.10%
12,847.00USD0.00%
12,847.00USD+278.97%
3,390.00USD-66.10%
10,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

StimCell Enegetics Stock analysis

What does StimCell Enegetics do? Cell MedX Corp. makes money through its subsidiary Avyonce Cosmedics Inc., which resells spa technology and equipment to the beauty and wellness industry. Avyonce also markets eBalance Technology, used for micro current treatments targeting diabetes and related ailments, and conducts observational studies with this technology. The company provides continuing education for estheticians and healthcare professionals in medical aesthetics. Avyonce Cosmedics Inc. serves the beauty and wellness industry, focusing on professionals who use spa technology and equipment. The firm develops a family of devices based on eBalance Technology, which is applied in treatments for diabetes and related conditions. This technology is central to Avyonce's product offerings and educational services. Cell MedX Corp. operates as a development stage company with no full-time employees, relying on its subsidiary Avyonce to drive revenue. The company's business model centers on the commercialization of eBalance Technology through product sales, educational programs, and observational studies in the medical aesthetics sector. StimCell Enegetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about StimCell Enegetics stock

Current Liabilities of StimCell Enegetics is 356,302.00 USD in 2026.

Current Liabilities of StimCell Enegetics changed from 835,070.00 USD to 356,302.00 USD, representing a -57.33% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities StimCell Enegetics since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's StimCell Enegetics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — StimCell Enegetics

All Key Metrics — StimCell Enegetics